|1.||Hypertension (High Blood Pressure)
|1.||Devereux, Richard B: 73 articles (11/2015 - 02/2002)|
|2.||Dahlöf, Björn: 66 articles (11/2015 - 02/2002)|
|3.||Kjeldsen, Sverre E: 53 articles (08/2015 - 03/2002)|
|4.||Wachtell, Kristian: 45 articles (11/2015 - 02/2002)|
|5.||Ibsen, Hans: 38 articles (08/2012 - 02/2002)|
|6.||Nieminen, Markku S: 30 articles (11/2015 - 03/2002)|
|7.||Lindholm, Lars H: 30 articles (06/2012 - 03/2002)|
|8.||Okin, Peter M: 29 articles (08/2015 - 03/2002)|
|9.||Julius, Stevo: 27 articles (07/2014 - 03/2002)|
|10.||Oparil, Suzanne: 21 articles (05/2010 - 03/2002)|
|1.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/01/1990 - "In some areas of clinical interest, such as the pathophysiology of left ventricular hypertrophy, ACE inhibitors are very useful for elucidating the possible influences of the renin-angiotensin system."
01/01/2014 - "Left ventricular hypertrophy among black hypertensive patients: focusing on the efficacy of angiotensin converting enzyme inhibitors."
07/01/2006 - "Initial studies suggest that ARBs and angiotensin-converting enzyme inhibitors may have similar effects in terms of reducing left ventricular hypertrophy, and the combination of angiotensin-converting enzyme inhibitors and ARBs is thought to be synergistic due to a more complete inhibition of the renin-angiotensin-aldosterone system. "
01/01/1993 - "Studies from other laboratories have shown that ACE inhibitors reverse left ventricular hypertrophy and improve left ventricular diastolic function. "
06/01/2013 - "In left-ventricular hypertrophy, ACE inhibitors were favoured, too (67%). "
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
03/01/2006 - "We examined the hypothesis that treatment with an angiotensin-converting enzyme inhibitor could be beneficial in the reversal of left ventricular hypertrophy in these patients. "
08/01/1998 - "Prolonged antihypertensive therapy might be less effective in reversing the left ventricular hypertrophy (LVH) in uremics bearing the deleted (DD) allele of the angiotensin converting enzyme (ACE) gene than in patients with the inserted (II) allele or in those heterozygous (ID) for the gene. "
12/01/2012 - "Large panels of studies have examined the association between angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and risk for left ventricular hypertrophy (LVH), yet with inconclusive results. "
01/01/2009 - "A recent study found that the angiotensin-converting enzyme (ACE) genotype also affects physiological left ventricular hypertrophy. "
01/01/2002 - "Analysis of gene-environment interactions by "stressing-the-genotype" studies: the angiotensin converting enzyme and exercise-induced left ventricular hypertrophy as an example."
12/01/1996 - "Calcium antagonists exert a range of beneficial effects in hypertensive patients, including reduction of blood pressure, improvement in myocardial blood flow, regression of left ventricular hypertrophy and cardioprotection in reperfused organs. "
11/02/1995 - "Many clinical studies have shown that calcium antagonists are effective in lowering blood pressure and can induce regression of left ventricular hypertrophy. "
01/01/1982 - "Calcium antagonist was effective in improving the delayed relaxation in patients with left ventricular hypertrophy, suggesting a role of calcium on delayed myocardial relaxation in the hypertrophied heart."
03/06/2015 - "This article critically reviews the limited observational data on associations between cTnT, BNP, NT-pro-BNP, coronary artery calcium, left ventricular hypertrophy, and carotid intima-media thickness with cardiovascular events and death in non-dialysis-dependent patients with CKD. "
01/01/2015 - "Cross-sectional analysis of serum calcium levels for associations with left ventricular hypertrophy in normocalcemia individuals with type 2 diabetes."
|4.||Losartan (Cozaar)FDA LinkGeneric
12/01/1995 - "(1) Midwall left ventricular performance was higher in Dahl S than Dahl R rats on a high-salt diet; (2) this elevation was partially independent of an increase in left ventricular chamber size, an indirect measure of preload; and (3) in Dahl S rats on losartan, increased left ventricular performance is related to improved contractility, associated with a blunted development of left ventricular hypertrophy."
11/01/2003 - "In another trial performed in patients with left ventricular hypertrophy (Losartan Intervention For Endpoint Reduction), a subset of patients had ISH. "
08/01/2003 - "In another trial performed in patients with left ventricular hypertrophy (Losartan Intervention For Endpoint Reduction ), a subset of patients had ISH. "
05/01/2003 - "Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study."
12/01/2008 - "Although losartan therapy and decreasing ECG left ventricular hypertrophy are associated with decreased AF incidence, the relationship of HR changes over time to development of AF has not been examined. "
|5.||Atenolol (Tenormin)FDA LinkGeneric
06/01/1987 - "The aim of this study is to evaluate the effects of chronic beta-blocking therapy (atenolol 100 mg/d) on ECG and ECG indexes of left ventricular hypertrophy (LVH) in hypertensive patients. "
05/01/2011 - "To the best of the authors' knowledge, this is the first documented case of severe dynamic left ventricular outflow tract obstruction and severe left ventricular hypertrophy in a cat successfully treated with oral atenolol."
08/09/2007 - "Conversely, in elderly hypertensives first-line beta-blockade (atenolol) has performed poorly in reducing cardiovascular risk (due to partial beta-2 blockade atenolol evokes metabolic disturbance and does not improve vascular compliance, or effectively lower central aortic pressure or reverse left ventricular hypertrophy). "
01/01/2003 - "Patients with echocardiographic left ventricular hypertrophy at baseline (n = 124) showed greater reduction of left ventricular mass index with Per/Ind (-11.3 +/- 15.4 g/m(2)) than atenolol (-5.3 +/- 15.1 g/m(2); p = 0.031). "
08/01/1987 - "Therefore, regression of left ventricular hypertrophy with atenolol-induced blood pressure control occurred as early as 4 weeks after starting therapy and was maintained thereafter without apparent compromise of left ventricular systolic function."
|6.||Antihypertensive Agents (Antihypertensives)IBA
01/01/1988 - "However, not all antihypertensive drugs seem equally effective in bringing about coronary regression of left ventricular hypertrophy (LVH). "
01/01/1987 - "However, not all antihypertensive drugs seem equally effective in bringing about coronary regression of left ventricular hypertrophy. "
12/01/1985 - "However, not all antihypertensive drugs seem equally effective in bringing about coronary regression of left ventricular hypertrophy (LVH). "
04/01/2012 - "Blood pressure and left ventricular hypertrophy (LVH) improved and the use of anti-hypertensive drugs decreased. "
05/01/1993 - "The efficacy of many antihypertensive drugs to decrease blood pressure and to reduce left ventricular hypertrophy has already been demonstrated. "
12/01/1994 - "This study was designed to assess the course of left ventricular mass by echocardiography in a population of 893 hypertensive patients with moderate left ventricular hypertrophy, treated with perindopril for 3 months. "
01/01/2006 - "2. The treatment with perindopril decreases blood pressure effectively independent of ACE gene I/D genotype and left ventricular hypertrophy. "
01/01/2006 - "2. The analysis of changes in haemostasis and RAS during treatment with perindopril in relation to left ventricular hypertrophy (group LVH+ and LVH-). "
10/04/2001 - "Perindopril increases arterial compliance and reverses left ventricular hypertrophy in hypertensive patients. "
08/01/1994 - "Both treatments lowered systolic blood pressure and reversed left ventricular hypertrophy, perindopril being slightly more efficient at the dose administered. "
09/01/1996 - "The aim of the study was to determine whether enalapril monotherapy can improve left ventricular diastolic dysfunction (LVDD) in young and mild hypertensive patients without concomitant left ventricular hypertrophy (LVH). "
02/15/2015 - "Enalapril or VS-105 alone significantly reduced left ventricular hypertrophy (LVH); VS-105 plus enalapril did not further reduce LVH. "
02/01/2007 - "In order to evaluate the effect of enalapril on haemodynamics and renal function in a pressure overload model, we prepared eight feline models of left ventricular hypertrophy (LVH) by banding of the aortic arch. "
02/01/2007 - "Effects of enalapril in cats with pressure overload-induced left ventricular hypertrophy."
12/01/1996 - "Antihypertensive treatment with enalapril and/or thiazide, induces normalisation of the LA function in parallel to left ventricular hypertrophy regression."
05/01/2004 - "Left ventricular hypertrophy in hypertensive patients in Indian primary care: prevalence and effect of treatment with sustained release indapamide."
10/01/2000 - "Effects of indapamide in rats with pressure overload left ventricular hypertrophy."
01/01/1993 - "Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study."
12/01/1990 - "The effects of a diuretic, indapamide, on the regression of left ventricular hypertrophy were studied in a group of 9 patients with mild hypertension treated in an open therapeutic trial over a 12 month period. "
07/01/2012 - "Indapamide has protecting effects in a variety of conditions associated with high cardiovascular risk, such as diabetes, left ventricular hypertrophy, nephropathy and stroke. "
|10.||Amlodipine (Norvasc)FDA LinkGeneric
01/01/2013 - "Monotherapy with S-amlodipine resulted in complete regression of left ventricular hypertrophy in 55% and normalization of left ventricular diastolic function in 62.4% of cases; significant improvement of brachial artery vasomotor function was also observed. "
04/01/1997 - "The aim of the study was to assess whether the hypotensive activity of amlodipine is associated with regression of left ventricular hypertrophy and improvement of impaired LV or right ventricular (RV) diastolic function or increasing of tolerance of physical activity in hypertensive patients. "
01/01/1999 - "We evaluated effect of amlodipine therapy on left ventricular (LV) mass and function indices in 34 elderly hypertensives having echocardiographic evidence of left ventricular hypertrophy (LVH). "
11/01/1996 - "[Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients]."
01/01/1995 - "Using digitized M-mode echocardiograms and 24-hour noninvasive ambulatory blood pressure monitoring, we evaluated the effects of 1 year treatment with amlodipine on left ventricular morphology and function in 10 hypertensives with left ventricular hypertrophy. "
|1.||Renal Dialysis (Hemodialysis)
07/01/2015 - "Left ventricular hypertrophy underwent significant reduction over 17 years in our hemodialysis patients. "
04/01/2014 - "Continued DW control achieved by periodical calf-BR measurement improved arterial stiffness and left ventricular hypertrophy with good tolerability in hemodialysis patients. "
06/01/2015 - "Long-term nocturnal hemodialysis leads to favorable cardiovascular remodeling with a reduction in cavity dimensions, regression of left ventricular hypertrophy, and an improvement in diastolic function, as assessed by both TTE and CMR."
02/01/2009 - "In addition, self-measured and ambulatory BPs seem to be better correlates of left-ventricular hypertrophy and mortality in hemodialysis patients compared with pre/post-dialysis BP. Emerging data suggest that out-of-office BP monitoring is superior to BP obtained in the clinic when predicting target-organ damage and prognosis. "
07/01/2008 - "Identification of patients with increased risk for development of left ventricular hypertrophy and application of appropriate therapy to attain target values of risk factors lead to regression of left ventricular hypertrophy, reduced cardiovascular morbidity and mortality rates and improved quality of life in patients treated with regular hemodialyses."
01/01/2010 - "The data obtained suggest that the Freedom SOLO stentless bioprosthesis shows excellent early clinical and hemodynamic results, resulting in a significant regression of left ventricular hypertrophy and improvement in left ventricular systolic function."
11/01/2011 - "The bioprosthesis also showed good hemodynamic performance, with a significant reduction of left ventricular hypertrophy."
01/01/2000 - "The use of a 21-mm Carpentier-Edwards Perimount bioprosthesis is associated with low transprosthetic gradients and significant reduction in left ventricular hypertrophy after aortic valve replacement. "
07/01/2005 - "Although stentless bioprostheses offer hemodynamic advantages, prosthetic valves of smaller size may provide less reduction of left ventricular hypertrophy and, therefore, affect survival and quality of life. "
03/01/2004 - "These analyses indicate that current bioprostheses have significantly better durability than discontinued bioprostheses, reveal a detrimental impact for smoking after AVR and MVR, and indicate an increased reoperation risk in patients with a small aortic bioprosthesis or with persistent left ventricular hypertrophy after AVR."
|3.||Transplantation (Transplant Recipients)
10/01/2014 - "Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular complications in renal transplant recipients. "
10/01/2014 - "Left ventricular hypertrophy in renal transplant recipients in the first year after transplantation."
01/01/2014 - "Left ventricular hypertrophy (LVH) is frequently observed in chronic dialysis patients and is also highly prevalent in kidney transplant recipients. "
08/27/2013 - "Arterial stiffness and left ventricular hypertrophy may significantly influence the intrarenal vascular resistance measured using Doppler sonography in stable kidney transplant recipients."
04/01/2013 - "Left ventricular hypertrophy is common in kidney transplant recipients. "
|4.||Prostheses and Implants (Prosthesis)
03/01/2006 - "During follow up, a left ventricular mass reduction occurred in patients with supra-annular implants (from 225 +/- 110 to 173 +/- 59 g/m2; p < 0.03), but not in patients with intra-annular implants (173 +/- 62 and 186 +/- 64 g/m2; p = 0.87) The study results showed that, compared to intra-annular implantation, supra-annular implantation of bioprosthetic stented valves in the aortic position was associated with a significantly better hemodynamic performance of the prosthesis and significant regression of left ventricular hypertrophy."
04/01/2005 - "Previous studies have reported that patient-prosthesis mismatch may be associated with lesser regression of left ventricular hypertrophy. "
07/01/2006 - "This aortic root enlargement aortoplasty and annuloplasty method can be calibrated to all AVRs involving stented manufactured prostheses when these are deemed the prosthesis of choice for the patient with a relatively small annulus and/or aortic root, severe left ventricular hypertrophy, compromised LV function or a very active lifestyle, to achieve predicted EOA values > or = 1.00 cm2/m2."
02/01/2006 - "The prevalence of residual left ventricular hypertrophy at follow-up was 50% in the group with patient-prosthesis mismatch and 50% in the group without patient-prosthesis mismatch (p=0.83). "
05/01/2002 - "However, the postoperative pressure gradient through the prosthesis and left ventricular hypertrophy remained at a high level in the small IOAI group."
01/01/2006 - "During the first 1 or 2 years on dialysis, patients on peritoneal dialysis (PD) have been shown to have an improvement in left ventricular hypertrophy, blood pressure, and volume status. "
06/01/2011 - "This study aimed to investigate the influence of different peritoneal dialysis regimens on blood pressure control, the diurnal pattern of blood pressure and left ventricular hypertrophy in patients on peritoneal dialysis. "
01/01/2008 - "The aim of the present study was to evaluate the relationship between ADMA levels, residual renal function, and left ventricular hypertrophy in peritoneal dialysis patients. "
01/01/2006 - "This study was undertaken to investigate the effect of long-term blood pressure (BP) reduction, achieved with salt restriction and strict volume control, on frequency and regression of left ventricular hypertrophy (LVH) in long-term peritoneal dialysis (PD) patients. "
01/01/2015 - "Predictors of left ventricular hypertrophy and their cutoffs in peritoneal dialysis patients."